Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) is described in its own communications as a leader in life science research and clinical diagnostics products. Based in Hercules, California, the company operates globally and regularly issues news on its financial performance, technology platforms, and corporate developments. This news page aggregates recent BIO stock headlines and company announcements.
Investors and analysts following Bio-Rad can find updates on quarterly financial results, including segment performance for the Life Science and Clinical Diagnostics groups and commentary on factors such as academic research funding, biotech funding conditions, and reimbursement trends in key markets. The company frequently discusses both GAAP and non-GAAP results, along with explanations of how non-GAAP measures are used in its internal analysis.
Bio-Rad’s news flow also covers product and technology updates, particularly around its Droplet Digital PCR (ddPCR) portfolio. Recent releases describe the launch of new ddPCR platforms, the integration of technologies from the acquisition of Stilla Technologies, and webinars or presentations focused on its ddPCR product line. These items provide insight into how the company is expanding its presence in genomics research and applied science applications.
Additional news items include announcements about participation in healthcare and investor conferences, leadership appointments, and historical and corporate milestones. For example, the company has reported on executive leadership changes and has issued statements regarding the passing of its co-founder and Director Emeritus, Alice N. Schwartz. Users interested in BIO news can use this page to review these updates in one place and to track how Bio-Rad communicates its strategy and operations over time.
Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, announced that CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 10:30 AM ET (7:30 AM PT). A live webcast and replay will be accessible via the Investor Relations section of Bio-Rad’s website.
Bio-Rad Laboratories, Inc. reported first-quarter 2024 financial results with total net sales of $610.8 million, a decrease of 9.8% compared to the same period in 2023. While Life Science segment sales dropped by 25.3%, Clinical Diagnostics segment sales increased by 4.7%. Net income for the quarter was $383.9 million, or $13.45 per share, compared to $69.0 million, or $2.32 per share, in 2023. Bio-Rad remains cautiously optimistic about a gradual biopharma market recovery and confident in their long-term strategy.
Bio-Rad Laboratories, Inc. will have its COO and CFO participate in a fireside chat during the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be webcasted and available for replay on the company's Investor Relations website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.